

**TITLE. USE CENTERED ARIAL BOLD CAPITAL, FONT SIZE 12.**Author’s names (first name and last name). Address, fax, and e-mail.   
Use centered Arial font, size 11.

*Keywords: Three keywords. Use centered Arial italic font, size 10.*

Use: Letter paper size; Margins 3 cm for the top, 2.5 cm for the left side, and 1.5 cm for the other sides; and 0.5 cm, between columns. Abstracts should be on one single page. Abstracts lacking one or more of the sections described here, or those written in less than 80% of a page, will not be accepted. Abstract submissions are to be evaluated by the Scientific Committee of the Congress. Optimize the space in order to write the most important features of your work, including the following sections.

**Introduction.** Try to write the introduction in just one paragraph. Do not leave blank spaces at the beginning or between paragraphs.

The aim of the work should be stated in a separate paragraph at the end of this section.

**Methods**. Explain the methodological strategy instead of describing each technique. You can cite the references of methods in order to optimize space. Scientific names should be written in *italics*. Use condensed formulas for chemical compounds. Concentration should be expressed in g/L or %, as preferred.

**Results and discussion**. You can include tables or figures in this section.

*Fig. 1. Figure captions: Use centered Arial italic font, size 9.*

*Titles should be concise and bellow figures*

*Table 1. Table captions: Use centered Arial italic font, size 9.*

*Do not use cells shadowing. Titles should be concise and above tables*

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  |  |  |
|  |  |  |

**Conclusions**. Be precise in writing the conclusions of your work.

**Acknowledgements**. You can include here the funding of your investigation.

**References**. Use justified Arial font size 9. Four references are an adequate number for an abstract of this length. They should be numbered in order of appearance, and indicated in brackets in the text. Quote articles, books or meeting abstracts as follows:

1. Last name, first name initials. (Year). Article title. *Abbreviated Journal name in italics*. Volume (issue number): page-page.

2. Last name, first name initials. (Year). Chapter title. In: *Book’s title in italics*. Editor’s Last name, first name initials. Publishing house, country. page-page.

3. Last name, first name initials. (Year). Abstract title. *Meeting title in italics.* Organizing entity. Meeting place and date. page-page.

**Notes**:

1. All section titles (Introduction, Methods, Results and discussion, Conclusions, Acknowledgments and References) should be written in **Arial bold font, size 10**. All other text should be written in Arial justified font, size 10, unless otherwise stated.
2. The abstract title, authors’ names, the author who will present the work, and the abstract need to be submitted at: **redbio\_isa@ciatej.mx**

Space for a figure

1. Once the abstract is thoroughly reviewed and approved by all authors, it should be converted to a PDF file. Only this format is accepted for evaluation.
2. The file should be of maximum 2 MB. If inserted images are too big, please convert them to JPEG format.
3. If accepted, the abstract will be reproduced WITHOUT any modification, just as it was submitted. Authors are responsible of its contents.
4. Please adjust the information of your abstract to one page. Be careful not to write about the logos of the event. **The abstract must be written in English.**

**IMPORTANT!!**

We ask you to indicate the subject in which your research will participate, indicating in the title of the "abstract" file that you send, the acronym of the subject according to the following table:

|  |  |
| --- | --- |
| **Subject** | **Clave** |
| **Plant Biotechnology** | |
| a. Plant tissue culture  b. Genetic improvement of plants  c. Green chemistry Bioprospecting  d. Innovations for plant breeding | T1-A  T2-B  T3-C  T4-D |
| **Biotechnology of soil microorganisms and plant** | |
| 1. Plant-pathogen interactions 2. Biologic control 3. Biopesticides 4. Biofertilization 5. Microbial ecology of the soil and the rhizosphere. 6. Bioremediation 7. Omics sciences and genome editing | T2-A  T2-B  T2-C  T2-D  T2-E  T2-F  T2-G |
| **Biotechnology and sustainability of production systems** | |
| 1. Development models and sustainable agriculture 2. Integral strategies for water management 3. Integrated management of plant pests and diseases 4. Impact of product from genetic improvement on nutrition 5. Applications or systems to confront adverse abiotic conditions | T3-A  T3-B  T3-C  T3-D  T3-E |
| **Biotechnology, business models and socioeconomic aspects** | |
| 1. Business models and entrepreneurship in biotechnology 2. Collaboration and linkups 3. Intellectual property rights and innovation 4. Alternative business models, management, technology transfer, and other forms of finance | T4-A  T4-B  T4-C  T4-D |
| **Frameworks and regulatory development in bioethics, biosafety, and human rights (biotechnology and society)** | |
| 1. Interactions between SDGs and the Convention on Biological Diversity 2. Regulatory progress in biosafety of biotechnology 3. Intellectual Property and Nagoya Protocol 4. Biotechnology and its interaction with society | T5-A  T5-B  T5-C  T5-D |
| **Livestock and aquaculture biotechnology** | |
| 1. Breeding and genetics 2. Nutrition 3. Health | T6-A  T6-B  T6-C |

|  |  |
| --- | --- |
| **Special Subject** | |
| **Biotechnological contributions to the use of herbicides and their impact** | |
| 1. Environmental impact of herbicides 2. Scientific and traditional knowledge for weed control 3. Detecting and monitoring technologies 4. Challenges and opportunities for the regulation of the sustained use of glyphosate and other herbicides | T7-A  T7-B  T7-C  T7-D |
| **Cannabis** | |
| 1. Biotechnology for production and use of cannabinoids 2. Crop management practices 3. Generation and standardization of by-products 4. Experiences and challenges of the regulatory framework | T8-A  T8-B  T8-C  T8-D |
| **Solutions and challenges in the face of COVID-19** | |
| 1. Vaccines against SARS-CoV-2 in early stages of development 2. Treatments against SARS-CoV-2 based on recombinant proteins, extracts, and metabolites 3. Alternative disinfectant agents against SARS-COV-2 4. Cost-effectiveness diagnosis against SARS-CoV-2 | T9-A  T9-B  T9-C  T9-D |